Showing results (71-80 of 584) with videos related to
Sort By:
Pageof 59
Expert Opinion on Drug Safety|November 21, 2018
Safety of osimertinib in EGFR-mutated non-small cell lung cancerLaura Mezquita, Andreea Varga, David PlanchardPresse Medicale (Paris, France : 1983)|September 4, 2013
Thymic tumours: an updateValentina Polo, Nicolas Girard, Benjamin BesseEuropean Respiratory Review : an Official Journal of the European Respiratory Society|September 2, 2014
New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of responseJessica Menis, Baktiar Hasan, Benjamin BesseThe European Respiratory Journal|May 2, 2015
Therapeutic management of ALK+ nonsmall cell lung cancer patientsBoris Duchemann, Luc Friboulet, Benjamin BesseCancers|July 24, 2021
Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176Edouard Auclin, Laura Mezquita, Benjamin BesseChinese Clinical Oncology|January 6, 2016
Methodology of clinical trials in lung cancerJessica Menis, Benjamin Besse, Denis LacombeCancer Cell|January 18, 2020
One or Two Immune Checkpoint Inhibitors?Caroline Robert, Emilie Lanoy, Benjamin BesseJournal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2018
Progress in the Management of Advanced Thoracic Malignancies in 2017Roberto Ferrara, Laura Mezquita, Benjamin BesseEuropean Respiratory Review : an Official Journal of the European Respiratory Society|October 7, 2021
The efficacy of immune checkpoint inhibitors in thoracic malignanciesJordi Remon, Francesco Facchinetti, Benjamin BesseBulletin Du Cancer|November 8, 2012
[Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]Julien Hadoux, Nicolas Girard, Benjamin BessePageof 59